Compare · DCOY vs NVS
DCOY vs NVS
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $262.33B, about 145070.6x DCOY ($1.8M).
- Over the past year, DCOY is down 95.1% and NVS is up 8.6% - NVS leads by 103.6 points.
- DCOY has been more active in the news (10 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Novartis AG
- Price
- $2.80+5.66%
- $137.41-0.19%
- Market cap
- $1.8M
- $262.33B
- 1M return
- -32.69%
- -12.36%
- 1Y return
- -95.06%
- +8.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 10
- 5
- Recent ratings
- 1
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest DCOY
- Director Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Chief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)
- Chief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)
- Chief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)
- Chief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)
- Director Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)
- Director Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)
- Director Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Director Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)
- Director Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)
Latest NVS
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG